Window of Opportunity for Durvalumab (MEDI4736) Plus Metformin Trial of in Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Metformin (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- 07 Oct 2019 Planned End Date changed from 1 Jan 2021 to 1 Apr 2021.
- 14 Jan 2019 Status changed from active, no longer recruiting to recruiting.
- 27 Nov 2018 Status changed from not yet recruiting to active, no longer recruiting.